公开(公告)号：US20190322734A1

公开(公告)日：2019-10-24

申请号：US15772664

申请日：2016-10-31

Applicant: GlaxoSmithKline Intellectual Property Development Limited

Inventor： Paul-Peter TAK

IPC: C07K16/24 ,  A61K39/395 ,  A61K31/519

Abstract: An antibody antagonist of GM-CSF for use in the treatment of a patient suffering from rheumatoid arthritis (RA), wherein said antibody is administered to said patient according to the following treatment regimen: i. a first period wherein the antibody is administered once a week; and ii. a second period wherein the antibody is administered every other week and then ceased once said patient has sustained remission for a continuous period of at least two months.

公开(公告)号：US20200231666A1

公开(公告)日：2020-07-23

申请号：US16829252

申请日：2020-03-25

Applicant: GlaxoSmithKline Intellectual Property Development Limited

Inventor： Paul-Peter TAK

IPC: C07K16/24 ,  A61K39/395 ,  A61K31/519

Abstract: An antibody antagonist of GM-CSF for use in the treatment of a patient suffering from rheumatoid arthritis (RA), wherein said antibody is administered to said patient according to the following treatment regimen: i. a first period wherein the antibody is administered once a week; and ii. a second period wherein the antibody is administered every other week and then ceased once said patient has sustained remission for a continuous period of at least two months.